Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV)

Completed · Phase 1

Conditions studied: Corneal Neovascularization

In brief

The purpose of this study is to determine the effectiveness and safety of ranibizumab (Lucentis) in treatment of corneal neovascularization.

Key facts

Study ID

NCT00681889

Run by

Reza Dana, MD

People needed

9

Starts

2008-04-01

Expected to finish

2010-09-01

Last updated by the study team

2012-11-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to provide written informed consent and comply with study assessments for the full duration of the study
• Age > 18 years old
• Patients with superficial or deep corneal neovascularization that extends farther than 2 mm from the limbus

You may not qualify if…

• Has received investigational therapy within 60 days prior to study entry
• Has received treatment with anti-VEGF agents (intraocular or systemic) within 45 days of study entry
• Concurrent use of systemic anti-VEGF agents
• Full thickness or lamellar keratoplasty within 90 days prior to study entry
• Ocular surface reconstruction within 90 days prior to study entry
• Other ocular surgeries within 90 days prior to study entry
• Corneal or ocular surface infection within 90 days prior to study entry
• Ocular or periocular malignancy
• Contact lens (excluding bandage contact lens) within 30 days prior to study entry
• Persistent epithelial defect (>1mm2 and ≥14 days duration) within 30 days prior to study entry
• Systemic, intravitreal, or periocular steroids within 30 days prior to study entry
• Change in dose/frequency of topical steroids and/or NSAIDs within 30 days prior to study entry
• Hypertension: systolic BP > 150 or diastolic BP > 90
• History of thromboembolic event within 6 months prior to study entry
• Current diagnosis of diabetes, Pregnancy (positive pregnancy test) or lactation
• Premenopausal women not using adequate contraception (The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch)
• Participation in another simultaneous medical investigation or trial.

Where it is running

• Massachusetts Eye and Ear Infirmary — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.